About Lomond Therapeutics

Lomond Therapeutics develops small molecule therapies targeting escape mutations in hematological cancers, addressing the challenge of treatment resistance in both hematological and solid malignancies. The company aims to deliver first and best-in-class medicines that improve patient outcomes by effectively overcoming these resistant mutations.

```xml <problem> Hematological cancers often develop resistance to treatment due to escape mutations, which limit the effectiveness of existing therapies. These mutations pose a significant challenge in both hematological and solid malignancies, leading to poor patient outcomes. </problem> <solution> Lomond Therapeutics is developing small molecule therapies specifically designed to target these escape mutations in hematological cancers. By focusing on resistant mutations, the company aims to deliver first-in-class and best-in-class medicines that can effectively overcome treatment resistance. These therapies are intended to improve patient outcomes by providing more effective treatment options for hematological malignancies. Lomond Therapeutics is a development stage spinout from Eilean Therapeutics, a biopharma company targeting resistant mutations in hematological and solid cancer malignancies. </solution> <features> - Small molecule therapies designed to target escape mutations. - Focus on hematological cancers with potential application in solid malignancies. - Aims to deliver first-in-class and best-in-class medicines. </features> <target_audience> The primary target audience includes patients with hematological cancers who have developed resistance to existing treatments, as well as the healthcare professionals who treat them. </target_audience> ```

What does Lomond Therapeutics do?

Where is Lomond Therapeutics located?

Lomond Therapeutics is based in San Diego, United States.

When was Lomond Therapeutics founded?

Lomond Therapeutics was founded in 2021.

How much funding has Lomond Therapeutics raised?

Lomond Therapeutics has raised 44000000.

Location

San Diego, United States

Founded

2021

Funding

44000000

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Lomond Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself!

Executive Summary

lomondther.com 10+

Crunchbase

Founded 2021 – San Diego, United States

Funding

Estimated Funding

$20M+

Team

No team information available.

Company Description

Problem

Hematological cancers often develop resistance to treatment due to escape mutations, which limit the effectiveness of existing therapies. These mutations pose a significant challenge in both hematological and solid malignancies, leading to poor patient outcomes.

Solution

Lomond Therapeutics is developing small molecule therapies specifically designed to target these escape mutations in hematological cancers. By focusing on resistant mutations, the company aims to deliver first-in-class and best-in-class medicines that can effectively overcome treatment resistance. These therapies are intended to improve patient outcomes by providing more effective treatment options for hematological malignancies. Lomond Therapeutics is a development stage spinout from Eilean Therapeutics, a biopharma company targeting resistant mutations in hematological and solid cancer malignancies.

Features

Small molecule therapies designed to target escape mutations.

Focus on hematological cancers with potential application in solid malignancies.

Aims to deliver first-in-class and best-in-class medicines.

Target Audience

The primary target audience includes patients with hematological cancers who have developed resistance to existing treatments, as well as the healthcare professionals who treat them.